Actively Recruiting
Risk-Adapted Chemotherapy Guided by EBV-DNA and MRI in Nasopharyngeal Carcinoma Patients Using De-concurrent Treatment Approach
Led by Fudan University · Updated on 2026-08-13
148
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a risk-adapted adjuvant therapy approach based on dynamic Epstein-Barr virus EBV DNA changes and MRI results in patients with nasopharyngeal carcinoma NPC. The study aims to determine if this tailored treatment improves the 2-year failure-free survival compared to a historical group receiving standard care. The trial focuses on patients with specific stages of NPC and uses a prospective single-center phase II design. Participants receive initial induction chemotherapy with gemcitabine and cisplatin, followed by intensity-modulated radiation therapy IMRT. After radiotherapy, patients are categorized into low, medium, or high risk based on EBV-DNA and MRI findings. The low-risk group undergoes clinical follow-up only, the medium-risk group receives capecitabine orally for eight cycles, and the high-risk group receives both tislelizumab intravenously and capecitabine orally for up to eight cycles, with possible maintenance of tislelizumab. During the study, participants undergo dynamic monitoring of EBV-DNA and MRI assessments. Researchers evaluate outcomes including 2-year failure-free survival, overall survival, locoregional and distant failure-free survival, adverse effects, and tumor response rates at various time points after IMRT. The trial monitors safety and treatment effects up to two years, with follow-up visits and evaluations throughout the period.
CONDITIONS
Brief Title
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
Research Team
X
Xiayun He, MD
F
Fen Xue, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here